Bharat Book

Pharmacogenomics Partnering Terms and Agreements

Press Release   •   Dec 11, 2013 09:59 IST

Dec 11, 2013 : Bharat Book Bureau presents the new report, on 'Pharmacogenomics Partnering Terms and Agreements'  provides a detailed understanding and analysis of how and why companies enter pharmacogenomics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 140 links to online copies of actual pharmacogenomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of pharmacogenomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in pharmacogenomics dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading pharmacogenomics deals since 2007. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top big pharma companies with a brief summary followed by a comprehensive listing of pharmacogenomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of pharmacogenomics partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of pharmacogenomics partnering deals signed and announced since January 2007. The chapter is organized by specific pharmacogenomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in pharmacogenomics partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of pharmacogenomics technologies and products.

Pharmacogenomics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to pharmacogenomics trends and structure of deals entered into by leading companies worldwide.

Pharmacogenomics Partnering Terms and Agreements includes:

Trends in pharmacogenomics dealmaking in the biopharma industry since 2007
Analysis of pharmacogenomics deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life pharmacogenomics deals
Access to over 140 pharmacogenomics contract documents
The leading pharmacogenomics deals by value since 2007
Most active pharmacogenomics dealmakers since 2007
The leading pharmacogenomics partnering resources

Table of Contents:
Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in pharmacogenomics dealmaking
2.1. Introduction
2.2. Pharmacogenomicss partnering over the years
2.3. Big pharma pharmacogenomics dealmaking activity
2.4. Most active pharmacogenomicss dealmakers
2.5. Pharmacogenomics partnering by deal type
2.6. Pharmacogenomics partnering by disease type
2.7 Average deal terms for pharmacogenomicss
2.7.1 Pharmacogenomics headline values
2.7.2 Pharmacogenomics upfront payments
2.7.3 Pharmacogenomics milestone payments
2.7.4 Pharmacogenomics royalty rates

Chapter 3 – Leading pharmacogenomics deals
3.1. Introduction
3.2. Top pharmacogenomics deals by value

Chapter 4 – Big pharma pharmacogenomics deals
4.1. Introduction
4.2. How to use big pharma pharmacogenomics partnering deals
4.3. Bigpharma pharmacogenomics partnering company profiles
Abbott
AstraZeneca
Bayer
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Novartis
Pfizer
Roche
Takeda

Chapter 5 – Pharmacogenomics dealmaking directory
5.1. Introduction
5.2. Company A-Z
5.3. By stage of development
Discovery
Marketed
Phase I
Phase II
Preclinical
5.4. By deal type
Asset purchase
Co-development
Collaborative R&D
Contract service
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Supply
5.5. By therapy area
Cardiovascular
Central Nervous SystemDermatology
Gastrointestinal
Genetic disorders
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Pediatrics
Psychiatry
Public Health
Respiratory
 

For more information kindly visit : http://www.bharatbook.com/healthcare-market-research-reports/pharmacogenomics-partnering-terms-and-agreements.html

Related link : http://www.bharatbook.com/market-research-report/pharmaceuticals-and-healthcare.html

About Bharat Book Bureau:

Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

In case the reports don't match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.

Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Email: info@bharatbook.com 
Website: www.bharatbook.com 
Follow us on twitter: https://twitter.com/researchbook 
Follow us on linked in : http://www.linkedin.com/company/bharat-book-bureau 
Our Blog : http://blog.bharatbook.com/ 


Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.